PT - JOURNAL ARTICLE AU - Kopel, Hagit AU - Araujo, Andre B. AU - Bogdanov, Alina AU - Zeng, Ni AU - Winer, Isabelle AU - Winer-Jones, Jessamine AU - Lu, Tianyi AU - Marks, Morgan A. AU - Bonafede, Mac AU - Nguyen, Van Hung AU - Martin, David AU - Mansi, James A. TI - Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis AID - 10.1101/2024.04.10.24305549 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.10.24305549 4099 - http://medrxiv.org/content/early/2024/04/12/2024.04.10.24305549.short 4100 - http://medrxiv.org/content/early/2024/04/12/2024.04.10.24305549.full AB - Background/Objectives COVID-19 continues to pose a significant burden that impacts public health and the healthcare system as the SARS-CoV-2 virus continues to evolve. Regularly updated vaccines are anticipated to boost waning immunity and provide protection against circulating variants. This study evaluated vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults ≥18 years, overall, and by age and underlying medical conditions.Methods This retrospective cohort study used the Veradigm Network EHR linked to claims data to identify US adults ≥18 years of age who received the mRNA-1273.815 vaccine (exposed) matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed). Patients in the unexposed cohort were randomly matched to eligible mRNA-1273.815 recipients. Inverse probability of treatment weighting was used to adjust for differences between the two cohorts. The exposed cohort was vaccinated between September 12, 2023, and December 15, 2023, and individuals in both cohorts were followed up for COVID-19-related hospitalizations and medically attended COVID-19 until December 31, 2023. A Cox regression model was used to estimate the hazard ratio (HR). VE of the mRNA-1273.815 vaccine in preventing COVID-19-related hospitalizations and any medically attended COVID-19 was estimated as 100*(1-HR). Subgroup analyses were performed for adults ≥50, adults ≥65, and individuals with underlying medical conditions associated with severe COVID-19 outcomes.Results Overall, 859,335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean age was 63 years, and 80% of the study population was ≥50 years old. 61.5% of the mRNA-1273.815 cohort and 66.4% of the unexposed cohort had an underlying medical condition. Among the overall adult population (≥18 years), VE was 60.2% (53.4–66.0%) against COVID-19-related hospitalization and 33.1% (30.2%–35.9%) against medically attended COVID-19 over a median follow-up of 63 (IQR: 44–78) days. VE estimates by age and underlying medical conditions were similar.Conclusions These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults 18 years and older, regardless of their vaccination history, and support CDC recommendations for vaccination with the 2023-2024 Omicron XBB.1.5-containing COVID-19 vaccine to prevent COVID-19-related outcomes, including hospitalizations.Competing Interest StatementA.B.A., D.M., H.K., J.A.M., M.A.M., and T.L. are employees of and shareholders in Moderna Inc. A.B., J.P.W.-J., N.Z., I.H.W., and M.B. are employees of Veradigm, which was contracted by Moderna and received fees for data management and statistical analyses. V.H.N. is an employee of VHN Consulting, which was contracted by Moderna to help conduct this analysis.Funding StatementThis work was supported by Moderna, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As a noninterventional, retrospective database study using a certified Health Insurance Portability and Accountability Act-compliant deidentified research database, approval by an institutional review board was not necessary.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study were used under license from Veradigm and Komodo Health. Due to data use agreements and its proprietary nature, restrictions apply regarding the availability of the data. Further information is available from the corresponding author.